title: Epicatechin inhibits human plasma lipid peroxidation caused by haloperidol in vitro.
abstract: Epicatechin belongs to flavonoids protecting cells against oxidative/nitrative stress. Oxidative/nitrative stress observed in schizophrenia may be caused partially by the treatment of patients with various antipsychotics. The aim of our study was to establish the effects of epicatechin and antipsychotics action (the first generation antipsychotic (FGA)--haloperidol and the second generation antipsychotic (SGA)--amisulpride) on peroxidation of plasma lipids in vitro. Lipid peroxidation in human plasma was measured by the level of thiobarbituric acid reactive species (TBARS). The properties of epicatechin were also compared with the action of a well characterized antioxidative commercial polyphenol-resveratrol (3,4',5-trihydroxystilbene) and quercetin (3,5,7,3',4'-pentahydroxyflavone). Amisulpride, contrary to haloperidol (after 1 and 24 h) does not significantly influence the increase of plasma TBARS level in comparison with control samples (P > 0.05). After incubation (1 and 24 h) of plasma with haloperidol in the presence of epicatechin we observed a significantly decreases the level of TBARS (P < 0.001, P < 0.001, respectively). In our other experiments, we found that epicatechin also decreased the amount of TBARS in human plasma treated with amisulpride. In conclusion, the presented results indicate that epicatechin-the major polyphenolic component of green tea reduced significantly human plasma lipid peroxidation caused by haloperidol. Moreover, epicatechin was found to be a more effective antioxidant, than the solution of pure resveratrol or quercetin.
authors.affiliation: Department of Affective and Psychotic Disorders, Medical University of Lodz, Czechoslowacka 8/10, 92-216 Lodz, Poland. tzn_lodz@post.pl
authors.forename: Anna
authors.initials: A
authors.lastname: Dietrich-Muszalska
authors.forename: Bogdan
authors.initials: B
authors.lastname: Kontek
authors.forename: Beata
authors.initials: B
authors.lastname: Olas
authors.forename: Jolanta
authors.initials: J
authors.lastname: Rabe-Jabłońska
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology*; D002392:Catechin / Q000494:pharmacology*; D005260:Female; D006220:Haloperidol / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male
chemical_list: D014150:Antipsychotic Agents; D002392:Catechin; D006220:Haloperidol
references.citation: Prostaglandins Leukot Essent Fatty Acids. 1996 Aug;55(1-2):33-43
references.pmid: 8888121
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2006 May;30(3):512-5
references.pmid: 16426720
references.citation: J Neuropsychiatry Clin Neurosci. 2005 Spring;17(2):227-31
references.pmid: 15939978
references.citation: Experientia. 1996 Sep 15;52(9):922-6
references.pmid: 8841522
references.citation: Schizophr Res. 2004 Sep 1;70(1):91-100
references.pmid: 15246468
references.citation: Schizophr Res. 2005 Oct 1;78(1):69-86
references.pmid: 16005189
references.citation: Biochem Pharmacol. 1995 Jan 31;49(3):359-65
references.pmid: 7857323
references.citation: Schizophr Res. 2006 Jan 31;81(2-3):291-300
references.pmid: 16309894
references.citation: Arch Pharm Res. 2004 Jan;27(1):94-8
references.pmid: 14969346
references.citation: Schizophr Bull. 1989;15(1):81-9
references.pmid: 2717890
references.citation: Neuropsychobiology. 2009;59(1):1-7
references.pmid: 19221441
references.citation: J Psychiatr Res. 2007 Oct;41(8):673-9
references.pmid: 16324716
references.citation: Biol Psychiatry. 1990 Sep 15;28(6):535-9
references.pmid: 1699612
references.citation: Neuropsychobiology. 2004;49(4):205-9
references.pmid: 15154399
references.citation: Biochem Biophys Res Commun. 2001 Dec 21;289(5):1334-8
references.pmid: 11741342
references.citation: Schizophr Res. 1998 Jun 22;32(1):1-8
references.pmid: 9690328
references.citation: Platelets. 2005 Nov;16(7):386-91
references.pmid: 16236599
references.citation: Curr Med Chem. 2008;15(18):1840-50
references.pmid: 18691042
references.citation: Int J Biochem Cell Biol. 2007;39(1):44-84
references.pmid: 16978905
references.citation: J Psychiatr Res. 2003 Jan-Feb;37(1):43-51
references.pmid: 12482469
references.citation: J Toxicol Sci. 2009 Feb;34(1):77-87
references.pmid: 19182437
references.citation: Psychiatry Clin Neurosci. 2010 Oct;64(5):469-75
references.pmid: 20923426
references.citation: World J Biol Psychiatry. 2010 Mar;11(2 Pt 2):276-81
references.pmid: 19225991
references.citation: Eur Neuropsychopharmacol. 2004 May;14(3):245-50
references.pmid: 15056484
references.citation: Hum Exp Toxicol. 2011 Feb;30(2):145-51
references.pmid: 20488842
references.citation: J Zhejiang Univ Sci B. 2006 Dec;7(12):981-6
references.pmid: 17111467
references.citation: Prostaglandins Leukot Essent Fatty Acids. 2007 Feb;76(2):73-85
references.pmid: 17197163
references.citation: Nutr Cancer. 2010;62(5):622-9
references.pmid: 20574923
references.citation: Psychopharmacology (Berl). 2001 Nov;158(2):140-5
references.pmid: 11702087
references.citation: Biochem Biophys Res Commun. 1997 Mar 6;232(1):164-8
references.pmid: 9125123
references.citation: Cell Biochem Funct. 1984 Jul;2(3):167-70
references.pmid: 6478540
references.citation: Platelets. 2009 Mar;20(2):90-6
references.pmid: 19235050
references.citation: J Neurochem. 1998 Sep;71(3):1002-12
references.pmid: 9721725
references.citation: J Nutr. 2000 Aug;130(8S Suppl):2073S-85S
references.pmid: 10917926
references.citation: CNS Drugs. 2001;15(4):287-310
references.pmid: 11463134